Radiolabeled Compounds for Diagnosis and Treatment of Cancer

• Autore: Kumar Krishan
• Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
• Descrizione fisica: 1 online resource (262 p.)
• Soggetto topico: Chemistry; Research and information: general
• Soggetto non controllato: 123,124,125,131I-labeled molecules and biomolecules; 124I-labeled monoclonal antibodies; 188Re-liposome; AAZTA; adrenergic receptor; aprepitant; biomolecules; breast; cancer; cancer imaging and therapy; cholecystokinin-2 receptor; cleavable linkers; DPP; EpCAM; FAP; fluorine-18; hypopharyngeal cancer; imaging; imaging pharmaceuticals; immunoPET imaging pharmaceuticals; iodine; kidney uptake; lutetium-177; microRNA; minigastrin; molecular imaging; monoclonal antibodies; n/a; neurokinin 1 receptor antagonist; neutral endopeptidase (NEP); NGS; peptides; PET; PET probes; PIB; positron emission tomography; positron emission tomography (PET); PREP; production processes; prostate-specific membrane antigen (PSMA); proteins; pyrazoles; radioiodination; radioiodine labeling; radiolabeling; radionuclide; radionuclide chelators; radionuclide therapy; radionuclides; radiopharmaceuticals; radiotracer; radiotracers; renal brush border enzymes; repeated therapy; SA; scandium-44; somatostatin analogs; SPECT; target-specific biomolecules; targeted radiotherapy
• Persona (resp. second.): KumarKrishan
• Sommario/riassunto: Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals.
• Titolo autorizzato: Radiolabeled Compounds for Diagnosis and Treatment of Cancer
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910557512703321
• Lo trovi qui: Univ. Federico II